Novartis today expressed disappointment at the National Institute for Health and Clinical Excellence's (NICE) preliminary recommendation to not recommend Jakavi™ (INC424, ruxolitinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycyth...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) has announced plans for the initiation of the Borealis-2 clinical trial, an investigator-sponsored, randomized, controlled Phase 2 study evaluating OGX-427 in patients with advanced or metastatic bladder cancer who have disease progression following initial platinum-based chemotherapy treatment...
Research on promising new therapies and data on the relative benefits of established treatments for genitourinary cancers were released, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 14-16, 2013, at the Rosen Shingle Creek in Orlando, FL...
Research on promising new therapies and data on the relative benefits of established treatments for genitourinary cancers were released, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 14-16, 2013, at the Rosen Shingle Creek in Orlando, FL...
Rethink Of How Ovaries Develop
2/13/2013
New research from the University of Adelaide will rewrite the textbooks on how an ovary is formed, as well as providing new insights into women's health and fertility. The study, now published in the journal PLOS ONE, also names a new type of cell that plays a key role in the development of ovaries and ovarian follicles, which are responsible for the production of eggs in women...
New Strategy Identified For Interfering With A Potent Cancer-Causing Gene
2/13/2013
Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics. CSHL Assistant Professor Christopher Vakoc, M.D., Ph.D...
The Therapeutic Effect Of RNAi Gene Silencing In Cancer Treatment
2/13/2013
The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules...
Rethink Of How Ovaries Develop
2/13/2013
New research from the University of Adelaide will rewrite the textbooks on how an ovary is formed, as well as providing new insights into women's health and fertility. The study, now published in the journal PLOS ONE, also names a new type of cell that plays a key role in the development of ovaries and ovarian follicles, which are responsible for the production of eggs in women...
New Strategy Identified For Interfering With A Potent Cancer-Causing Gene
2/13/2013
Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics. CSHL Assistant Professor Christopher Vakoc, M.D., Ph.D...
Genetic Root To Early-Onset Prostate Cancer Identified
2/13/2013
Prostate cancer is often considered an elderly man's disease, and little is known about the approximately 2% of cases that arise in men who are aged 50 years or younger. Research published in Cell Press journal Cancer Cell uncovers the genetic origin of such early-onset prostate cancer...